Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 8-K (Current Report)
Date of Report: February 12, 2024
Reporting Period: Events occurring on February 12 and February 13, 2024.
Business Overview: The Company is engaged in the development of treatments for coronavirus-derived human infections through a license agreement with TheraCour Pharma, Inc.
Key Financial Metrics and Agreements
This filing details material definitive agreements rather than periodic financial performance metrics (revenue, profit, cash flow). Key financial terms include:
- Line of Credit: A $2,000,000 standby facility with Dr. Anil R. Diwan (CEO) bearing 12% fixed interest. As of the filing date, no amounts have been drawn.
- Milestone Payments: The Company has paid Milestones 1, 2, and 3 to TheraCour. Future cash milestones (originally totaling up to $10.5 million) are now contingent on a "Revenue Event."
- Collateral: The Line of Credit is secured by a mortgage on the Company's real property in Shelton, Connecticut, and a chattel mortgage on equipment.
Material Changes Versus Prior Period
The filing reports three significant amendments to existing agreements:
- Amendment to License Agreement (Feb 13, 2024): Unearned and unremitted cash milestone payments to TheraCour are no longer due on a fixed schedule. Instead, they are payable only upon a "Revenue Event" (defined as profit from grants, partnerships, commercialization, or contract work). Financing proceeds (equity, debt, mortgage) are explicitly excluded from this definition. Furthermore, no more than 50% of recognized revenue from such events will be applied to these payments.
- Line of Credit Extension (Feb 12, 2024): The maturity date of the $2,000,000 credit facility with Dr. Diwan was extended from December 31, 2024, to December 31, 2025.
- Suspension of Advance Payment (Feb 12, 2024): The requirement to maintain an advance with TheraCour equal to two months of projected invoices has been suspended until the Company raises sufficient capital. Existing advances will be applied to current invoices.
Outlook, Risks, and Management Commentary
Liquidity and Capital Needs: The suspension of the advance payment requirement and the restructuring of milestone payments indicate a focus on preserving cash. The suspension of the advance is explicitly tied to the Company's ability to "raise sufficient capital."
Risks and Contingencies:
- Payment Obligations: Future cash obligations to TheraCour are now entirely dependent on the Company generating profitable revenue, which introduces uncertainty regarding future cash outflows.
- Debt Maturity: While the Line of Credit maturity was extended, the facility remains undrawn and secured by the Company's primary real property and equipment.
Investor Verification Checklist
- Verify the Company's current cash position and runway given the suspension of the TheraCour advance requirement.
- Review the definition of "Revenue Event" in the amended License Agreement to understand the threshold for triggering future milestone payments.
- Confirm the status of any ongoing capital raising efforts mentioned as the condition for resuming advance payments.
- Monitor the utilization of the $2,000,000 Line of Credit, noting it is currently undrawn but secured by company assets.